Estimating treatment effects on health utility scores for patients living with migraine: a post hoc analysis of the DELIVER trial

• DOI: 10.1080/14737167.2023.2219898
• Publication Date: 2023-05-31T15:14:35Z
• Authors: Linus Jönsson; Stephane A. Regnier; Steven Kymes; Susanne F. Awad; Brian Talon; Xin Ying Lee; Peter J. Goadsby
• Keywords: Treatment Outcome; Double-Blind Method; Migraine Disorders; Humans; 3. Good health

This post hoc analysis aimed to estimate eptinezumab’s therapeutic effect on health utilities and determined to which extent monthly migraine days (MMDs) explain changes in health utilities. DELIVER, a randomized, double-blind, placebo-controlled phase 3b trial (NCT04418765), investigated eptinezumab efficacy and safety in patients with 2-4 prior migraine treatment failures. Regression analysis explored the relationship between utility scores and MMDs, with eptinezumab treatment as a covariate along with MMDs to identify any MMD-independent effect on utilities. Path analysis quantified eptinezumab’s impact as mediated through MMD reduction. The base case model showed that each reduction in MMD was associated with a mean utility score increase (0.0189; 95% CI: 0.0180, 0.0198; P < 0.001). Mean utility score was generally higher for eptinezumab versus placebo, justifying addition of treatment effect to the base case model. Patients administered eptinezumab had on average 0.0562 (95% CI: 0.0382, 0.0742; P < 0.001) higher utility versus placebo when controlling for number of MMDs. From path analysis, MMD reduction resulting from eptinezumab treatment accounted for 53% additional utility gain observed in patients. Changes in MMDs alone inadequately captured migraine’s impact on patient utility, as there was also a positive eptinezumab-driven, treatment-specific impact on utility score. The trial is registered at ClinicalTrials.gov (CT.gov identifier: NCT04418765).